Number: 201102468 Principal Investigator: Lockhart, A. Craig
Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
Phase: I Disease Site: Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out more information about how safe CEP-9722 is in certain types of cancers. In both Part 1 and Part 2, we are also trying to find out how much of the study drug stays in your blood over a certain period of time, and want to see if the study drug affects your type of cancer. If you agree to participate, you will be enrolled in Part 1 of the study.
More Information:
Internal Protocol Documents (requires Siteman administrative database password)